Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)

Yao Zhu; Dingwei Ye; Expert Group

doi:10.2147/CMAR.S236879

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)

Cancer Manag Res. 2020 Mar 23:12:2127-2140. doi: 10.2147/CMAR.S236879. eCollection 2020.

Authors

Yao Zhu^{1

2}, Dingwei Ye^{1

2}; Expert Group

Affiliations

¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
² Department of Oncology, Shanghai Medical School, Fudan University, Shanghai, People's Republic of China.

Abstract

Currently, the basic treatment of advanced prostate cancer is still endocrine therapy, but almost all patients eventually progress to castration-resistant prostate cancer (CRPC). In 2016, the Chinese Expert Consensus on the Diagnosis and Treatment of CRPC which aimed to help Chinese clinicians formulate treatment plans for CRPC was published. In this 2019 update, the 2016 version was updated with the aim of providing a more appropriate reference for clinical practice, standardizing CRPC patient management, and facilitating decision-making. The consensus is evidence-based and reviews the optimal therapeutic recommendations for CRPC management in China by taking into consideration the clinical characteristics of Chinese patients; drug availability, efficacy and safety; and recent advancements and developments in the international medical arena.

Keywords: castration-resistant; expert consensus; metastases; prostate cancer; treatment.